PhorMed's lead technology, RP-323, is a
gene repair therapy
Discovering new approaches to therapy in the field of genomic medicine.
We are a biopharmaceutical company focused on the development and commercialization of RP-323, a targeted gene repair, immunotherapy, and stem cell activator for treating neurological diseases, cancers and blood disorders.
We are happy to announce that you can now be part of this exciting technology and help make a difference by investing in PhorMed through Equity Crowdfunding.
RP-323 treats diseases upstream where issues start. It has the ability to add a needed phosphate to a pathway turning the switch on or off inside the DNA (differentiation), clearing the pathway allowing transcription of DNA and expresses a protein producing a change such as cell division (proliferation) or cause cell death(apoptosis).
After multiple clinical studies RP-323 has been found to be safe and the company is now prepared to enter into the next phase of clinical trials advancing its pipeline in collaboration with two clinical sites in Atlanta Georgia.
